Phase III clinical trial - Sein Adjuvant

MonarchE (I3Y-MC-JPCF)
Sein Adjuvant
Essai clinique fermé
Public cible
Adulte
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Description de l'essai
The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer
Vignette
PAUL-HENRI COTTU
Investigateur principal
Vignette
PAUL-HENRI COTTU
Investigateur principal